论文部分内容阅读
目的探讨p75NTR、D2-40和P63肌上皮标记物在乳腺纤维腺瘤、导管内癌和浸润性导管癌中的表达,鉴别乳腺癌组织中浸润性导管癌与导管内癌并检测其HER-2基因状态。方法用EnVision法对68例乳腺纤维腺瘤、导管内癌和浸润性导管癌分别进行p75NTR、D2-40和P63免疫染色,用FISH技术检测28例乳腺癌组织中浸润性导管癌和导管内癌的HER-2基因状态。结果 p75NTR、D2-40、P63在乳腺纤维腺瘤与导管原位癌中的表达差异没有统计学意义,在导管原位癌与浸润性导管癌中的表达差异有统计学意义。同时对28例乳腺癌组织切片上的浸润癌和导管内癌部分进行HER-2基因检测,二者HER-2基因状态的一致率为7.14%(2/28)。结论联合使用p75NTR、P63和D2-40是比较理想的乳腺肌上皮细胞的标记物,应用这些抗体保证检测乳腺浸润性导管癌HER-2基因的准确性。
Objective To investigate the expression of p75NTR, D2-40 and P63 myoepithelial markers in breast fibroadenoma, ductal carcinoma and invasive ductal carcinoma, and to identify invasive ductal carcinoma and intraductal carcinoma in breast cancer and to detect their HER-2 Gene Status. Methods EnVision method was used to immunostaining p75NTR, D2-40 and P63 in 68 cases of breast fibroadenoma, ductal carcinoma and invasive ductal carcinoma respectively. FISH was used to detect invasive ductal carcinoma and intraductal carcinoma in 28 cases of breast cancer HER-2 gene status. Results The expression of p75NTR, D2-40 and P63 in breast fibroadenoma and ductal carcinoma in situ was not statistically different, and there was significant difference between ductal carcinoma in situ and invasive ductal carcinoma. Meanwhile, HER-2 gene was detected in 28 cases of invasive carcinoma and intraductal carcinoma in breast cancer tissue sections. The coincidence rate of HER-2 gene status was 7.14% (2/28). Conclusion The combination of p75NTR, P63 and D2-40 is an ideal marker of mammary myoepithelial cells. These antibodies are used to ensure the accuracy of detecting HER-2 gene in breast invasive ductal carcinoma.